Le Lézard
Classified in: Health
Subjects: NPT, SVY, SCZ

Ahead of an Imminent Medicare Coverage Decision, New Morning Consult Survey Shows More than 2/3 of Americans Support Broadening Access to a Less-Invasive Heart Valve Disease Treatment for Rural Communities


WASHINGTON, June 17, 2019 /PRNewswire/ -- Ahead of a final decision from the Centers for Medicare & Medicaid Services (CMS) that may continue to limit Medicare coverage for a heart valve disease treatment called transcatheter aortic valve replacement (TAVR), a new survey shows that Americans support expansion of access to the procedure for rural patients.

Alliance for Aging Research logo (PRNewsfoto/Alliance for Aging Research)

The new Morning Consult poll, commissioned for the Alliance for Aging Research, sampled a nationally representative group of 1,995 registered voters and an oversample of 500 rural adults ages 65+, and found that more than two-thirds (69%) of Americans across every demographic?including gender, age, income, and community population density?agree that it is important to expand access to TAVR to rural communities. Among rural adults over age 65, support climbs to 81%.

Compared to open-heart surgery, TAVR allows patients to wake up just a few hours later and be discharged from the hospital within a few days. Not surprisingly nine in ten adults who voiced an opinion in the survey, said they would be more likely to choose TAVR for themselves over surgical aortic valve replacement (SAVR).

"These results remind us that we cannot forget the difficulties that older, rural Americans face in accessing healthcare," notes Susan Peschin, MHS, President and CEO of the Alliance for Aging Research. "Policy decisions that require individuals to travel long distances to receive an FDA-approved treatment are not in the patient's best interest. After seven years of limited access in order to collect more evidence on TAVR, it's time for CMS to widen coverage to all Medicare beneficiaries the agency is changed to serve."

The survey also found that:

TAVR is a minimally invasive treatment for severe symptomatic aortic stenosis. Aortic stenosis is one of the most common types of heart valve disease, and it can be debilitating, costly, and deadly. Left untreated, the prognosis for severe aortic stenosis is dire: 50% of patients die two years after symptoms develop and only 20% may be alive at five years. Worse, more than two thirds of people with it are never diagnosed or treated, particularly minorities and rural Americans.

Unfortunately, strict Medicare coverage requirements, limit access to TAVR. Greater than 90% of TAVR procedures are performed in urban, teaching hospitals, and 78% of patients served by these hospitals are in higher income zip codes. Less than 5% of essential hospitals that fill a safety net role in their communities offer the procedure.

To learn more about the survey visit www.agingresearch.org/TAVRaccesssurvey. To read more about the position of the Alliance and the 15 other organizations that submitted comments to CMS regarding the pending decision, go to www.agingresearch.org/TAVRNCD.

About the Alliance for Aging Research:
The Alliance for Aging Research is the leading nonprofit organization dedicated to accelerating the pace of scientific discoveries and their application to vastly improve the universal human experience of aging and health. The Alliance was founded in 1986 in Washington, D.C., and has since become a valued advocacy organization and a respected influential voice with policymakers.

Contact: Jim Bowers
press@agingresearch.org

SOURCE Alliance for Aging Research


These press releases may also interest you

at 05:00
Governments across the country have been denying Canadians access to vital information about the novel coronavirus and their responses to it, while failing to protect whistleblowers who could expose threats to public health ? whether they are in...

at 04:56
kneat.com, inc. ("Kneat"), announces that the Company will release its Financial Results for the quarter ended March 31, 2020 after TSX market close on Wednesday 27 May 2020. ...

at 04:35
The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and...

at 04:23
Enzymatica and its partner STADA have extended its agreement for the cold spray ViruProtect® (ColdZyme) to cover another 19 countries in Europe. With the extended agreement STADA has provided order estimates of about SEK 20 million for 2020. The...

at 04:00
As governments in many countries are easing lockdown restrictions, fitness facilities are getting ready to re-open and welcome back customers. After the pandemic, health has certainly risen to the top of the list of consumers' personal priorities,...

at 03:30
The "Global Molecular Point of Care (mPOC) Devices Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The molecular point of care (mPOC) devices market is poised to grow by $ 816.62 million during 2020-2024 progressing at...



News published on 17 june 2019 at 12:38 and distributed by: